Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
Go back to Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases| AKEBIA THERAPEUTICS (NASDAQ: AKBA) | Delayed: 0.90 -0.02 (2.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.92 | 52 Week High | $13.20 | |||
| Open | $0.93 | 52 Week Low | $7.00 | |||
| Day High | $0.94 | P/E | N/A | |||
| Day Low | $0.87 | EPS | $0.00 | |||
| Volume | 8,715,948 | |||||
